Risk stratification in medulloblastoma: Screening for molecular markers;Screening molekularbiologischer marker zur risikostratifizierung bei medulloblastomen

Klinische Padiatrie

Volumn 218, Issue 3, 2006, Pages 139-142

  Ebinger, M ^a   Senf, L ^a   Scheurlen, W ^b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Abteilung für Anästhesie und Intensivmedizin   (Germany)

^c Cnopfsche Kinderklinik   (Germany)

Author keywords

c MYC; Medulloblastoma; Promoter methylation

Indexed keywords

CASPASE 8; MOLECULAR MARKER; PROTEIN P16; RNA; UVOMORULIN;

ARTICLE; CANCER RISK; CANCER SCREENING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; MEDULLOBLASTOMA; METHYLATION; ONCOGENE C MYC; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRATIFICATION; TUMOR SUPPRESSOR GENE;

CASPASE 8; CASPASES; CEREBELLAR NEOPLASMS; CHILD; DNA METHYLATION; GENE AMPLIFICATION; GENETIC MARKERS; GENETIC SCREENING; HUMANS; MEDULLOBLASTOMA; NERVE TISSUE PROTEINS; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33744460523     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933413     Document Type: Article

References (12)

1. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63: 441-449
2. Ebinger M, Senf L, Wachowski O, Scheurlen W. Promotor methylation pattern of caspaseS, P16INK4A, MGMT, TIMP3, and E-cadherin in medulloblastoma. Pathol Oncol Res 2004; 10: 17-21
3. Ebinger M, Senf L, Wachowski O, Scheurlen W. Expression of GAS7 in childhood CNS tumors. Pediatr Blood Cancer 2005; 46: 325-328
4. Frühwald MC, O'Dorisio MS, Dai Z, Tanner SM, Balster DA, Gao X, Wright FA, Plass C. Aberrant promotor methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene 2001; 36: 5033-5042
5. Fulda S, Debatin KM. INFgamma sensitizes for apoptosis by upregulating caspase 8 expression through the STAT1 pathway. Oncogene 2002; 15: 2295-2308
6. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004; 22: 984-993
7. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase 8 expression. Oncogene 2000; 19: 4604-4610
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428
9. Ju YT, Chang AC, She BR, Tsaur ML, Hwang HM, Chao CC, Cohen SN, Lin-Chao S. A gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated Purkinje neurons affects neurite formation. Proc Natl Acad Sci USA 1998; 95: 11423-11428
10. Packer RJ. Childhood medulloblastoma: progress and future challenges. Brain Dev 1999; 21: 75-81
11. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998; 16: 2478-2485
12. Scheurlen WG, Schwabe GC, Seranski P, Joos S, Harbott J, Metzke S, Dohner H, Poustka A, Wilgenbus K, Haas OA. Mapping of the breakpoints on the short arm of chromosome 17 in neoplasms with an i(17q). Genes Chromosomes Cancer 1999; 25: 230-240